Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381719 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
NCT00381719: Completed Phase 2 study, sponsored by Allergan.
NCT00381719 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 330 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (148% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00381719, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
Study Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy
Interventions
- DRUG placebo capsule
- DRUG AGN 203818
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
What the finished NCT00381719 record still lists
NCT00381719 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (148% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo capsule is the first listed.
NCT00381719 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00381719 about?
NCT00381719 is a clinical study titled "Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy". This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy
What is the current status of trial NCT00381719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2006-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00381719?
The interventions under investigation include: placebo capsule (DRUG), AGN 203818 (DRUG).
Who is sponsoring clinical trial NCT00381719?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00381719's enrollment target sits among peer trials
330 145th of 2000 higher than 1,855 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia